The Sj&#246;gren&#39;s Tool for Assessing Response (STAR) demonstrates its ability to accurately detect treatment efficacy in 17 recent RCTs in Sj&#246;gren&#39;s disease

Benlysta (belimumab) - GSK

Rhapsido (remibrutinib) - Novartis

hydroxychloroquine - Generic mfg.

Rituxan (rituximab) - Roche

dazodalibep (HZN-4920) - Amgen

leflunomide - Generic mfg.

iscalimab (CFZ533) - Novartis

baminercept (BG 9924) - Biogen

Actemra IV (tocilizumab) - Roche, JW Pharma, Chugai Pharmaceutical

Orencia (abatacept) - BMS

ianalumab (VAY736) - Novartis

https://eppro02.ativ.me/web/page.php?page=session&project=ACR26&id=3564539

Raphaele Seror1; gabriel Baron2; Elodie Perrodeau3; Alena Piatrova4; Hendrika Bootsma5; Simon Bowman6; Jacques-Eric Gottenberg7; Michele Bombardieri8; Suzanne Arends5; Benjamin A. Fisher9; Wolfgang Hueber10; Andre van Maurik11; Joel van Roon12; Valérie Devauchelle-Pensec13; Christopher Collins14; Neal Jain15; Peter Gergely16; Xavier Mariette17; Raphael Porcher18

Sep 8, 2026